OICHARTS
8 AMThe 8 AM report →

ANIP

ANI Pharmaceuticals, Inc. · XNAS · 131 sessions on record
$72.65▲ +0.03 · 0.0%from $72.62 the session before · Sep 30, 2026 close · end of day
Open
$73.01
High
$73.84
Low
$72.37
Day's range
$1.52.0% of the previous close
VWAP
$72.86close −0.29% from it
Volume, shares
384K0.91× the 20-session average
Traded, $
$28.0M
Trades
6.42K60 shares per trade
Previous close
$72.62+0.03 to the close
Market cap
$1.77Bat the close of Sep 30
Day range19% of the way up
$72.37$73.84
52-week range17% of the way up
$69.58 Sep 11$87.76 May 8

−17% from the high · +4.4% from the low

Options

No listed options on ANIP

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
ANIP close over the last 126 sessions, with S&P 500 rebased to the first close62.8376.5090.18axis spans 44%S&P 500ANIPApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 44 percent.

Quarterly results

consolidated · latest filed Aug 7, 2026 · SEC filings

Revenue $266.0M, +26% on a year earlier; profit $24.7M, +190% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of ANIP on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 7$266.0M▲ +26%$24.7M▲ +190%1.05▼ −3.2%S&P 500 0.0% · −3.2 pp
Mar 2026filed May 8$237.5M▲ +20%$29.5M▲ +88%1.28▼ −3.8%S&P 500 +0.2% · −4.1 pp
Dec 2025filed Feb 27$247.1M▲ +30%$27.5M—1.14—not reached
Sep 2025filed Nov 7$227.8M▲ +54%$26.6M—1.13—not reached
Jun 2025filed Aug 7$211.4M▲ +53%$8.5M—0.36▼ −3.2%S&P 500 0.0% · −3.2 pp
Mar 2025filed May 8$197.1M▲ +43%$15.7M▼ −14%0.69▼ −3.8%S&P 500 +0.2% · −4.1 pp
Dec 2024filed Feb 28$190.6M▲ +45%−$10.3M▼ −990%-0.45—not reached
Sep 2024filed Nov 7$148.3M▲ +13%−$24.2M▼ −340%-1.27—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of ANIP on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$883.4M▲ +44%$78.3M—3.32
FY24to Dec 2024$614.4M▲ +26%−$18.5M▼ −200%-1.04
FY23to Dec 2023$486.8M▲ +54%$18.8M—0.85
FY22to Dec 2022$316.4M▲ +46%−$47.9M—-3.05
FY21to Dec 2021$216.1M▲ +3.7%−$42.6M—-3.40

Fundamentals

consolidated · filings to Jun 2026 · close $72.65 on Sep 30

ANIP trades at 16 times trailing earnings against 20 for its industry, 3.0 times book value, revenue +31% over twelve months, market cap $1.77B.

Valuation
Market cap
$1.77Bon Sep 30
Price to earnings
16consolidated · four quarters to Jun 2026 · industry 20
Trailing EPS
$4.60diluted · consolidated · four quarters to Jun 2026
Price to book
3.0consolidated · balance sheet to Jun 2026
Book value a share
$24.45consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
21%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
1.8market cap over revenue, four quarters to Jun 2026
Shares outstanding
24.4Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$978.4Mfour quarters to Jun 2026
Revenue growth, 12 months
▲ +31%against the twelve months before
Revenue 3-year CAGR
▲ +35%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$108.3Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks
Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
StockMarket capP/EP/BClose $
REGNRegeneron Pharmaceuticals Inc$71.24Bon Sep 3019consolidated2.3$758.27
UTHRUnited Therapeutics Corp$23.24Bon Sep 3019consolidated3.6$541.89
RPRXRoyalty Pharma plc Class A Ordinary Shares$22.65Bon Sep 3031consolidated—$58.36
BMRNBioMarin Pharmaceuticals Inc$11.61Bon Sep 30150consolidated1.8$60.00
LQDALiquidia Corporation Common Stock$2.71Bon Sep 3022consolidated14$30.26
ANIPANI Pharmaceuticals, Inc.$1.77Bon Sep 3016consolidated3.0$72.65
STOKStoke Therapeutics, Inc. Common Stock$1.68Bon Sep 30—4.9$26.00
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$995.7Mon Sep 30—2.3$11.70
JBIOJade Biosciences, Inc. Common Stock$893.5Mon Sep 301.7consolidated2.0$14.05
CLYMClimb Bio, Inc. Common Stock$658.8Mon Sep 30—2.8$11.47

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 190% of shares, BlackRock, Inc. the largest at 24%, Soleus Capital Management, L.P. 7.1% and VANGUARD CAPITAL MANAGEMENT LLC 6.9%, as filed for the quarter to Jun 2026.

Held by 13F managers
190%of shares outstanding
Shares held
45.2M+0.60% on Mar 2026 among managers filing both
Managers holding
283253 a quarter earlier
Largest holder
24%BlackRock, Inc.
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of ANIP
ManagerSharesOf outstandingValueChange on quarter
BlackRock, Inc.5.92M24%$489.8M+422K
Soleus Capital Management, L.P.1.74M7.1%$143.7M+95K
VANGUARD CAPITAL MANAGEMENT LLC1.68M6.9%$138.8M+30.3K
STATE STREET CORP1.66M6.8%$137.7M+120K
TANG CAPITAL MANAGEMENT LLC1.42M5.8%$117.1Munchanged
DIMENSIONAL FUND ADVISORS LP1.25M5.1%$103.2M+185K
AMERICAN CENTURY COMPANIES INC1.15M4.7%$95.1M+766K
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1.12M4.6%$93.0M−4.69K
Global Alpha Capital Management Ltd.1.12M4.6%$92.4M+394K
GEODE CAPITAL MANAGEMENT, LLC1.07M4.4%$88.8M+94.4K
Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

ANIP insider trades
InsiderTradeSharesPriceHeld after
CAREY STEPHEN P.Officersold · Jun 29, 20262,850$84.12177,543
Cook MeredithOfficersold · Jun 12, 2026500$82.0377,890
HAUGHEY THOMASDirectorsold · Jun 8, 20262,000$80.8838,878
HAUGHEY THOMASDirectorgranted · May 21, 20264,357$0.0040,878
TANNENBAUM RENEE PDirectorgranted · May 21, 20264,357$0.0029,514
Pera Antonio RDirectorgranted · May 21, 20264,357$0.0027,017
Leonard Matthew JDirectorgranted · May 21, 20264,357$0.0011,221
Thoma JeanneDirectorgranted · May 21, 20264,357$0.0027,762
CAREY STEPHEN P.Officersold · Jun 5, 20263,312$80.00180,393
CAREY STEPHEN P.Officerexercised · Jun 5, 20263,312$49.51183,705

Corporate actions

exchange records

No corporate action on record for ANIP yet.

Price history

131 sessions on record · to Sep 30 · end of day

ANIP is +1.0% over 20 sessions against the S&P 500's +0.1%, 17% below its 52-week high, realised volatility 31% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $ANIP %S&P 500 %Difference pp
120 sessionssince Apr 9$80.14▼ −9.3%▲ +12%−22
60 sessionssince Jul 7$85.99▼ −16%▲ +2.0%−18
20 sessionssince Sep 1$71.92▲ +1.0%▲ +0.11%+0.91
5 sessionssince Sep 23$74.43▼ −2.4%▼ −0.67%−1.7
1 sessionsince Sep 29$72.62+0.04%▼ −0.21%+0.25
Averages of the closeclose against each average
5-session average
$73.63close −1.3% from it
20-session average
$73.29close −0.87% from it
50-session average
$75.53close −3.8% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$2.53.4% of the close
Average day's range, 20
$2.12.9% of the close
Volume against 20 sessions
0.91×384K vs 413K average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
31%≈ ±2.0% a session · moved more than that on 6 of 20
Realised volatility, 60
30%≈ ±1.9% a session · moved more than that on 16 of 60
Beta to S&P 500, 60
0.07moved with S&P 500 on 29 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
11 up · 9 downof 20
Last 60 sessions
27 up · 33 downof 60
Best session, 250
▲ +5.3%Jun 4
Worst session, 250
▼ −5.3%Aug 7

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 55% of reported volume on Sep 30, 2026, against 58% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
ANIP daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 202647.8K87.2K54.9%
Sep 29, 202665.5K112K58.6%
Sep 28, 202692.6K128K72.1%
Sep 25, 202639.8K81.5K48.9%
Sep 24, 202680.4K126K63.9%
Sep 23, 2026123K197K62.5%
Sep 22, 2026101K137K74.2%
Sep 21, 2026177K247K71.9%
Sep 18, 2026199K238K83.6%
Sep 17, 2026132K214K61.4%

Filings

SEC EDGAR · newest first
ANIP SEC filings
FiledFormReport date
Sep 30, 20264Sep 29, 2026
Sep 16, 20264Sep 15, 2026
Sep 15, 2026144—
Sep 14, 20264Sep 14, 2026
Sep 14, 20264Sep 11, 2026
Sep 11, 2026144—
Sep 1, 20264Aug 31, 2026
Aug 27, 20264Aug 19, 2026
Aug 27, 20263Aug 19, 2026
Aug 26, 20264Aug 25, 2026
Aug 25, 2026144—
Aug 24, 20268-KAug 19, 2026
Aug 13, 20264Aug 13, 2026
Aug 11, 20264Aug 10, 2026
Aug 7, 202610-QJun 30, 2026
Aug 7, 20268-KAug 7, 2026
Jul 30, 20264Jul 29, 2026
Jul 29, 2026144—
Jul 27, 2026SCHEDULE 13G/A—
Jul 21, 20264Jul 18, 2026
Jul 17, 2026S-8—
Jul 14, 20264Jul 13, 2026
Jul 7, 2026144—
Jul 6, 20264Jul 2, 2026
Jun 30, 20264Jun 29, 2026

About ANI Pharmaceuticals, Inc.

SEC and exchange records
Company
ANI Pharmaceuticals, Inc.
Exchange
XNAS
Industry
Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK
1023024
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:41 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.